Contents 2 min read
Claim and source comparison
Comparison limited to the Viola 1995 animal/laboratory abstract, Amsterdam 2009 chamomile-extract trial abstract and NCCIH chamomile safety information. Not a full clinical review of pure apigenin.
· Bounded source comparison; not a complete clinical review or independent medical endorsement.
Animal study
Viola et al. (1995) examined apigenin affinity for a benzodiazepine binding site in the laboratory and anxiety-like behavior measures in mice. Some experimental doses produced no sedation; a tenfold increase produced a mild sedative effect.
Mouse behavior and receptor binding are not evidence of human sleep treatment or a clinical GABA-A effect. Animal doses were not converted into human doses or a verified interaction with sedative medicines.
Source 2 · Abstract read
Human randomized controlled trial
Amsterdam et al. (2009) randomized 57 people with mild-to-moderate generalized anxiety disorder to chamomile extract or placebo for eight weeks. Change in the primary HAM-A score favored extract (P = 0.047); the study did not test pure apigenin.
This is a small, short preliminary trial, underpowered for small secondary-outcome differences. A chamomile-extract result cannot be transferred to pure apigenin, chamomile tea or insomnia treatment.
Source 3 · Abstract read
Official safety summary
NCCIH describes serious allergic reactions and reported warfarin interactions for chamomile; possible sedative interactions are theoretical. This information concerns chamomile products, not the clinical safety profile of pure apigenin.
Plant safety information does not prove identical risks or safety for an isolated molecule. The sources read do not establish long-term, pregnancy/breastfeeding or medication-combination safety of pure apigenin.
Source 4 · Official summary read
What is Apigenin?
2026-11-11 correction: Mouse apigenin findings were separated from a human chamomile-extract trial. Safety, combination and mechanism claims transferred to pure apigenin, and unverified adverse-event frequencies, were removed.
Apigenin is a flavonoid found in chamomile and other plants. Findings on calming mechanisms are mostly preclinical; chamomile extract trials do not establish pure apigenin as a sleep or anxiety treatment.
Mechanism of Effect
Viola et al. (1995) examined apigenin affinity for a benzodiazepine binding site in the laboratory and anxiety-like behavior measures in mice. Some experimental doses produced no sedation; a tenfold increase produced a mild sedative effect.
Mouse behavior and receptor binding are not evidence of human sleep treatment or a clinical GABA-A effect. Animal doses were not converted into human doses or a verified interaction with sedative medicines.
Clinical Evidence
Amsterdam et al. (2009) randomized 57 people with mild-to-moderate generalized anxiety disorder to chamomile extract or placebo for eight weeks. Change in the primary HAM-A score favored extract (P = 0.047); the study did not test pure apigenin.
This is a small, short preliminary trial, underpowered for small secondary-outcome differences. A chamomile-extract result cannot be transferred to pure apigenin, chamomile tea or insomnia treatment.
Dose information and research limits
Dose information and research limits
This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.
The sources reviewed do not establish a validated sleep or anxiety dose, onset or oral half-life for pure apigenin. Chamomile tea, plant extract and the isolated molecule cannot be treated as equivalent.
These sources do not establish clinical efficacy or safety of pure apigenin combined with melatonin. Different substance classes do not establish complementarity or a personal combination recommendation.
Safety and Side Effects
NCCIH describes serious allergic reactions and reported warfarin interactions for chamomile; possible sedative interactions are theoretical. This information concerns chamomile products, not the clinical safety profile of pure apigenin.
Plant safety information does not prove identical risks or safety for an isolated molecule. The sources read do not establish long-term, pregnancy/breastfeeding or medication-combination safety of pure apigenin.
Related research and reading
These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.
Educational guides
- Sleep and Nootropics: Human Studies and Limits
Melatonin, magnesium and other supplements have been studied using different sleep measures; subjective improvement is not proof of deeper sleep or a safe nightly protocol.
Sources
- Salehi, B. et al. (2019). The therapeutic potential of apigenin. International Journal of Molecular Sciences, 20(6), 1305. (Genel derlemedir; spesifik mekanizma iddiaları için orijinal çalışmalar incelenmelidir.) PubMed · PMID 30875872
- Viola, H. et al. (1995). Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Medica, 61(3), 213–216. PubMed · PMID 7617761
- Amsterdam, J.D. et al. (2009). A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. Journal of Clinical Psychopharmacology, 29(4), 378–382. PubMed · PMID 19593179
- NIH NCCIH. Chamomile: Usefulness and Safety. https://www.nccih.nih.gov/health/chamomile NIH NCCIH
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
Apigenin is a flavonoid found in chamomile and other plants. Findings on calming mechanisms are mostly preclinical; chamomile extract trials do not establish pure apigenin as a sleep or anxiety treatment.
No established timeframe
These sources do not establish clinical efficacy or safety of pure apigenin combined with melatonin. Different substance classes do not establish complementarity or a personal combination recommendation.
The sources reviewed do not establish a validated sleep or anxiety dose, onset or oral half-life for pure apigenin. Chamomile tea, plant extract and the isolated molecule cannot be treated as equivalent.
Plant safety information does not prove identical risks or safety for an isolated molecule. The sources read do not establish long-term, pregnancy/breastfeeding or medication-combination safety of pure apigenin.